The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Eudocia Quant Lee
Consultant or Advisory Role - Genentech
David A. Reardon
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
David Schiff
Consultant or Advisory Role - Roche/Genentech
Jan Drappatz
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
Sean Aaron Grimm
Consultant or Advisory Role - Roche/Genentech
Andrew David Norden
No relevant relationships to disclose
Lakshmi Nayak
No relevant relationships to disclose
Rameen Beroukhim
No relevant relationships to disclose
Mikael L. Rinne
No relevant relationships to disclose
Andrew S. Chi
No relevant relationships to disclose
Tracy Batchelor
Consultant or Advisory Role - Kirin Pharmaceuticals; Merck; Novartis; Proximagen; Roche
Research Funding - AstraZeneca; Millennium; Pfizer
Kelly Hempfling
No relevant relationships to disclose
Christine Sceppa McCluskey
No relevant relationships to disclose
Katrina H. Smith
No relevant relationships to disclose
Sarah C. Gaffey
No relevant relationships to disclose
Brendan Wrigley
No relevant relationships to disclose
Jeffrey J. Raizer
Consultant or Advisory Role - Novartis; Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech (B)
Patrick Y. Wen
Consultant or Advisory Role - Novartis; Roche/Genentech
Research Funding - Genentech; Novartis